157 related articles for article (PubMed ID: 12801295)
1. Fludarabine plus cyclophosphamide for the treatment of advanced chronic lymphocytic leukemia.
Schiavone EM; De Simone M; Palmieri S; Annunziata M; Pocali B; Copia C; D'Amico MR; Vecchio LD; Ferrara F
Eur J Haematol; 2003 Jul; 71(1):23-8. PubMed ID: 12801295
[TBL] [Abstract][Full Text] [Related]
2. Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma.
Hendry L; Bowen A; Matutes E; Swansbury J; Catovsky D
Leuk Lymphoma; 2004 May; 45(5):945-50. PubMed ID: 15291353
[TBL] [Abstract][Full Text] [Related]
3. Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy.
Marotta G; Bigazzi C; Lenoci M; Tozzi M; Bocchia M; Lauria F
Haematologica; 2000 Dec; 85(12):1268-70. PubMed ID: 11114133
[TBL] [Abstract][Full Text] [Related]
4. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL.
Johnson S; Smith AG; Löffler H; Osby E; Juliusson G; Emmerich B; Wyld PJ; Hiddemann W
Lancet; 1996 May; 347(9013):1432-8. PubMed ID: 8676625
[TBL] [Abstract][Full Text] [Related]
5. Consolidation therapy with high-dose cyclophosphamide improves the quality of response in patients with chronic lymphocytic leukemia treated with fludarabine as induction therapy.
Weiss MA; Glenn M; Maslak P; Rahman Z; Noy A; Zelenetz A; Scheinberg DA; Golde DW
Leukemia; 2000 Sep; 14(9):1577-82. PubMed ID: 10995003
[TBL] [Abstract][Full Text] [Related]
6. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia.
O'Brien SM; Kantarjian HM; Cortes J; Beran M; Koller CA; Giles FJ; Lerner S; Keating M
J Clin Oncol; 2001 Mar; 19(5):1414-20. PubMed ID: 11230486
[TBL] [Abstract][Full Text] [Related]
7. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
O'Brien S; Moore JO; Boyd TE; Larratt LM; Skotnicki A; Koziner B; Chanan-Khan AA; Seymour JF; Bociek RG; Pavletic S; Rai KR
J Clin Oncol; 2007 Mar; 25(9):1114-20. PubMed ID: 17296974
[TBL] [Abstract][Full Text] [Related]
8. Cladribine combined with cyclophosphamide is highly effective in the treatment of chronic lymphocytic leukemia.
Robak T; Błoński JZ; Kasznicki M; Góra-Tybor J; Dwilewicz-Trojaczek J; Stella-Hołowiecka B; Wołowiec D
Hematol J; 2002; 3(5):244-50. PubMed ID: 12391542
[TBL] [Abstract][Full Text] [Related]
9. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia.
Eichhorst BF; Busch R; Hopfinger G; Pasold R; Hensel M; Steinbrecher C; Siehl S; Jäger U; Bergmann M; Stilgenbauer S; Schweighofer C; Wendtner CM; Döhner H; Brittinger G; Emmerich B; Hallek M;
Blood; 2006 Feb; 107(3):885-91. PubMed ID: 16219797
[TBL] [Abstract][Full Text] [Related]
10. Conventional dose fludarabine-based regimens are effective but have excessive toxicity in elderly patients with refractory chronic lymphocytic leukemia.
Shvidel L; Shtalrid M; Bairey O; Rahimi-Levene N; Lugassy G; Shpilberg O; Polliack A; Berrebi A;
Leuk Lymphoma; 2003 Nov; 44(11):1947-50. PubMed ID: 14738148
[TBL] [Abstract][Full Text] [Related]
11. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia.
Wierda W; O'Brien S; Wen S; Faderl S; Garcia-Manero G; Thomas D; Do KA; Cortes J; Koller C; Beran M; Ferrajoli A; Giles F; Lerner S; Albitar M; Kantarjian H; Keating M
J Clin Oncol; 2005 Jun; 23(18):4070-8. PubMed ID: 15767647
[TBL] [Abstract][Full Text] [Related]
12. Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study).
Robak T; Jamroziak K; Gora-Tybor J; Stella-Holowiecka B; Konopka L; Ceglarek B; Warzocha K; Seferynska I; Piszcz J; Calbecka M; Kostyra A; Dwilewicz-Trojaczek J; Dmoszyñska A; Zawilska K; Hellmann A; Zdunczyk A; Potoczek S; Piotrowska M; Lewandowski K; Blonski JZ
J Clin Oncol; 2010 Apr; 28(11):1863-9. PubMed ID: 20212251
[TBL] [Abstract][Full Text] [Related]
13. Fludarabine combined with cyclophosphamid is highly effective in the treatment of chronic lymphocytic leukemia.
Tóthová E; Kafková A; Fricová M; Guman T; Stecová N
Neoplasma; 2003; 50(6):433-7. PubMed ID: 14689065
[TBL] [Abstract][Full Text] [Related]
14. Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group.
Hallek M; Schmitt B; Wilhelm M; Busch R; Kröber A; Fostitsch HP; Sezer O; Herold M; Knauf W; Wendtner CM; Kuse R; Freund M; Franke A; Schriever F; Nerl C; Döhner H; Thiel E; Hiddemann W; Brittinger G; Emmerich B;
Br J Haematol; 2001 Aug; 114(2):342-8. PubMed ID: 11529853
[TBL] [Abstract][Full Text] [Related]
15. Oral fludarabine and cyclophosphamide as front-line chemotherapy in patients with chronic lymphocytic leukemia. The impact of biological parameters in the response duration.
Laurenti L; Tarnani M; De Padua L; Efremov DG; Zini G; Garzia M; Piccirillo N; Chiusolo P; Sorà F; Innocenti I; Sica S; Leone G
Ann Hematol; 2008 Nov; 87(11):891-8. PubMed ID: 18587576
[TBL] [Abstract][Full Text] [Related]
16. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.
Flinn IW; Neuberg DS; Grever MR; Dewald GW; Bennett JM; Paietta EM; Hussein MA; Appelbaum FR; Larson RA; Moore DF; Tallman MS
J Clin Oncol; 2007 Mar; 25(7):793-8. PubMed ID: 17283364
[TBL] [Abstract][Full Text] [Related]
17. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.
Keating MJ; O'Brien S; Albitar M; Lerner S; Plunkett W; Giles F; Andreeff M; Cortes J; Faderl S; Thomas D; Koller C; Wierda W; Detry MA; Lynn A; Kantarjian H
J Clin Oncol; 2005 Jun; 23(18):4079-88. PubMed ID: 15767648
[TBL] [Abstract][Full Text] [Related]
18. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
19. The combination of fludarabine, cyclophosphamide, and granulocyte-macrophage colony-stimulating factor in the treatment of patients with relapsed chronic lymphocytic leukemia and low-grade Non-Hodgkin's lymphoma.
Rao R; Shammo JM; Enschede SH; Porter C; Adler SS; Venugopal P; Gregory SA
Clin Lymphoma; 2005 Jun; 6(1):26-30. PubMed ID: 15989703
[TBL] [Abstract][Full Text] [Related]
20. Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia.
Bosch F; Ferrer A; López-Guillermo A; Giné E; Bellosillo B; Villamor N; Colomer D; Cobo F; Perales M; Esteve J; Altés A; Besalduch J; Ribera JM; Montserrat E;
Br J Haematol; 2002 Dec; 119(4):976-84. PubMed ID: 12472576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
